Valo Therapeutics Announces Two European Patents Granted for its Lead Asset PeptiCRAd-1 in Immuno-Oncology
16 févr. 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer and infectious diseases, announces it has been...
Innovation Pharmaceuticals Plans for Phase 2 Trial of New Treatment for Ulcerative Colitis
05 mars 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
Active ulcerative colitis targeted; multiple ascending dose design (low, mid, high doses and placebo)Endpoints: clinical remission (Mayo scoring); endoscopic remission; biomarkers, and others ...